Hospital dischargedata for Guillain-Barré syndrome and influenza a (H1N1) vaccine adverse events

Emerging Infectious Diseases

Volumn 16, Issue 9, 2010, Pages 1500-1501

  Jones, Timothy F ^a   McMillian, Marcy ^a   Boothe, Effie ^a   Hanna, Samir ^a   Ingram, L Amanda ^a  

^a TENNESSEE DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

CONTROLLED STUDY; DISEASE SURVEILLANCE; GUILLAIN BARRE SYNDROME; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; INFLUENZA A (H1N1); INFLUENZA VACCINATION; LETTER; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PREDICTION; UNITED STATES; ELECTRONIC MEDICAL RECORD; HEALTH SURVEY; INFLUENZA VIRUS A H1N1; STATISTICS;

GUILLAIN-BARRE SYNDROME; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; PATIENT DISCHARGE; POPULATION SURVEILLANCE; TENNESSEE;

EID: 77956026056     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1609.091837     Document Type: Letter

References (10)

1. Centers for Disease Control and Prevention. Safety of influenza A (H1N1) 2009 monovalent vaccines-United States, October 1-November 24, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:1-6.
2. Iskander J, Broder K. Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience. Expert Rev Vaccines. 2008;7:75-82. DOI:10.1586/14760584.7.1.75
3. Iskander J, Haber P, Herrera G. Monitoring vaccine safety during an influenza pandemic. Yale J Biol Med. 2005;78:265-75.
4. Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, et al. Guillain- Barré syndrome following influenza vaccination. JAMA. 2004;292:2478-81. DOI: 10.1001/jama.292.20.2478
5. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939-50. DOI: 10.1016/S1474-4422(08)70215-1
6. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32:150-63. DOI:10.1159/000184748
7. Mullooly JP, Donahue JG, DeStefano F, Baggs J, Eriksen E. Predictive value of ICD-9-CM codes used in vaccine safety research. Methods Inf Med. 2008;47:328-35.
8. France EK, Glanz JM, Xu S, Davis RL, Black SB, Shinefield HR, et al. Safety of the trivalent inactivated influenza vaccine among children: a populationbased study. Arch Pediatr Adolesc Med. 2004;158:1031-6. DOI: 10.1001/archpedi.158.11.1031
9. Bogliun G, Beghi E. Validity of hospital discharge diagnoses for public health surveillance of the Guillain-Barré syndrome. Neurol Sci. 2002;23:113-7. DOI: 10.1007/s100720200036
10. Sejvar J, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter N, et al. Guillain-Barré syndrome and Fisher syndrome: case definition and guidelines for collection, analysis and presentation of immunization safety data. Atlanta: Centers for Disease Control and Prevention; 2009 [cited 2010Apr 26]. http://www.brightoncollaboration.org